Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics, Inc. develops clinical-stage, oncology-focused antibody therapeutics targeting angiogenesis, immune activation and tumor-driven immunosuppression. News about CMPX centers on its antibody pipeline, including tovecimig, a DLL4 x VEGF-A bispecific antibody studied with paclitaxel in biliary tract cancer, and earlier-stage programs such as CTX-8371, CTX-10726 and CTX-471.
Recurring updates cover clinical trial results, FDA-related regulatory designations and interactions, medical-meeting presentations, pipeline expansion, financial results, cash resources, leadership changes and equity inducement grants under Nasdaq rules.
Compass Therapeutics (Nasdaq: CMPX) announced the appointments of Arjun Prasad, MBA, MPH as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, effective January 1, 2026.
Mr. Prasad joins from Servier Pharmaceuticals and has led >10 oncology launches including the 2024 launch of VORANIGO and commercialization of TIBSOVO for biliary tract cancer. Dr. Sirard joins from Leap Therapeutics with prior leadership at Sanofi and Genzyme, and has guided programs through IND filings, clinical development, pivotal trials, and regulatory approval. Management says these hires strengthen Compass’s ability to advance tovecimig and its oncology pipeline.
Compass Therapeutics (Nasdaq: CMPX) will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026. The presentation is scheduled for 7:30 AM PT and will be webcast at cmpx.info/jpmorgan.
Virtual replay and an archived copy will be available on Compass’ Events page. Compass is also hosting investor meetings as part of the LifeSci Partners Corporate Access Event on January 12–13, 2026 in San Francisco. Investors seeking one-on-one meetings should contact their J.P. Morgan or LifeSci representative to request meetings.
Compass Therapeutics (Nasdaq: CMPX) will participate in two investor events in December 2025: the Piper Sandler 37th Annual Healthcare Conference in New York on Dec 2, 2025 at 8:00 AM ET and the Evercore 8th Annual Healthcare Conference in Coral Gables on Dec 4, 2025 at 10:00 AM ET.
Live webcasts are provided for each presentation and recordings will be archived for 90 days on Compass’ Events page. Management will be available for one-on-one meetings during both events; interested investors should contact their representatives to request meetings.
Compass Therapeutics (NASDAQ:CMPX) reported Q3 2025 results and a clinical update. The company had $220 million in cash and marketable securities as of September 30, 2025, which management expects will provide runway into 2028. Clinical highlights include a met primary endpoint for tovecimig in COMPANION-002 and pooled OS/PFS analyses expected in late Q1 2026 (triggered at 80% pooled OS events). CTX-8371 Phase 1 fully enrolled with no dose-limiting toxicities and cohort expansions for NSCLC and TNBC planned in Q4 2025. CTX-10726 IND filing is planned for Q4 2025 with initial data expected in H2 2026.
Compass Therapeutics (Nasdaq: CMPX) presented preclinical data on CTX-10726, a tetravalent bispecific antibody targeting PD-1 and VEGF-A, at the 40th SITC Annual Meeting on November 7, 2025.
Key findings: CTX-10726 showed high-affinity binding to human and cynomolgus VEGF-A and PD-1, dose-dependent blockade of VEGF-A/VEGFR2 and PD-1/PD-L1 interactions, and potent IFN-γ immunomodulatory activity in vitro. In vivo, CTX-10726 produced tumor elimination in multiple models and demonstrated superior anti-tumor activity versus comparator antibodies including ivonescimab and bevacizumab in xenograft and knock-in mouse models. The company said an IND submission is on track for Q4 2025. Presentation materials will be posted on the company website after the meeting.
Compass Therapeutics (Nasdaq: CMPX) will participate in three investor events in November 2025: Guggenheim Healthcare Innovation Conference in Boston on Nov 10, 2025 at 3:30 PM ET, Stifel 2025 Healthcare Conference in New York on Nov 12, 2025 at 4:00 PM ET, and Jefferies Global Healthcare Conference in London on Nov 20, 2025 at 12:00 PM GMT.
Each presentation will be webcast; links are provided and presentations will be archived for 90 days on Compass’ Events page for replay.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology biopharmaceutical company, has announced its participation in four major investor conferences in September 2025:
- Citi's Biopharma Back to School Conference in Boston (Sept 2)
- Cantor Global Healthcare Conference in New York (Sept 3, 2:10 PM ET)
- H.C. Wainwright Global Investment Conference in New York (Sept 8, 11 AM ET)
- Morgan Stanley Global Healthcare Conference in New York (Sept 9, 5:35 PM ET)
All presentations will be archived for 90 days on Compass' Events page.
Compass Therapeutics (NASDAQ: CMPX), a clinical-stage oncology biopharmaceutical company, has announced the pricing of an upsized public offering totaling $120 million. The offering consists of 33,290,000 shares of common stock priced at $3.00 per share and pre-funded warrants to purchase 6,710,000 shares at $2.9999 per warrant.
The underwriters have a 30-day option to purchase up to 6 million additional shares. The offering is expected to close around August 14, 2025. The company plans to use the proceeds for commercial readiness preparations, research and clinical development of product candidates, and general corporate purposes.
Compass Therapeutics (NASDAQ: CMPX), a clinical-stage oncology biopharmaceutical company, has announced a proposed public offering of common stock and pre-funded warrants. The offering includes a 30-day option for underwriters to purchase additional shares under the same terms.
The company plans to use the proceeds for commercial readiness preparations, research and clinical development of its product candidates, and general corporate purposes. Jefferies, Piper Sandler, and Guggenheim Securities are serving as joint active bookrunning managers for the offering.
The offering will be conducted through a shelf registration statement on Form S-3 that was declared effective by the SEC on September 6, 2024.
Compass Therapeutics (NASDAQ:CMPX) reported Q2 2025 financial results and provided updates on its oncology pipeline. The company reported a net loss of $19.9 million ($0.14 per share), compared to $13.1 million in Q2 2024. Key highlights include promising survival data for tovecimig in biliary tract cancer, with secondary endpoint analysis now expected in Q1 2026.
In the CTX-8371 Phase 1 trial, two significant partial responses were observed in post-checkpoint inhibitor settings, including 100% tumor reduction in a lung cancer patient and >90% reduction in a breast cancer patient. The company's new drug CTX-10726 showed superior results compared to ivonescimab in preclinical studies.
Compass ended Q2 with $101 million in cash, providing runway into 2027. R&D expenses increased 47% year-over-year to $16.4 million, primarily due to manufacturing costs for tovecimig and CTX-10726.